Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
Johnson & Johnson(JNJ) stock is priced at $244.40, giving the company a market capitalization of 588.98B. It carries a P/E multiple of 21.98 and pays a dividend yield of 2.1%.
During the trading session on 2026-03-31, Johnson & Johnson(JNJ) shares reached a daily high of $245.33 and a low of $242.65. At a current price of $244.40, the stock is +0.7% higher than the low and still -0.4% under the high.
Trading volume for Johnson & Johnson(JNJ) stock has reached 3.9M, versus its average volume of 8.16M.
The stock's 52-week range extends from a low of $141.50 to a high of $251.71.
The stock's 52-week range extends from a low of $141.50 to a high of $251.71.
JNJ News
Key Points Johnson & Johnson is a Dividend King. The company's strong operations suggest regular payout increases aren't a thing of the past. 10 stocks we li...
IBD Stock Of The Day Why Johnson & Johnson Is Rebounding — Finally Licensing Johnson & Johnson Johnson & Johnson JNJ $ 243.60 $1.11 0.46% 32% IBD Stock Analysis...
Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has...
Analyst ratings
59%
of 29 ratingsMore JNJ News
Extreme Fear is Gripping the Market, This Is the Smart Move Most Investors Miss. By Rich Duprey Published Mar 31, 8:09AM EDT Quick Read Apple (AAPL), Microsof...
Oppenheimer raised the firm’s price target on Alumis to $55 from $50 and keeps an Outperform rating on the shares. The firm sees the three new orals for psorias...
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
Johnson & Johnson (NYSE:JNJ) has secured European approval for self or caregiver administration of Darzalex in multiple myeloma. The decision covers all ten ap...
Monte Rosa Therapeutics, Inc. recently reported a fourth-quarter 2025 net loss of US$46.14 million and entered a supply agreement with Johnson & Johnson to eval...
Johnson & Johnson announced new long-term 52-week data from the Phase 3 Iconic-Advance 1 and 2 and Iconic-Lead studies, which assessed the efficacy and safety o...
In March 2026, Johnson & Johnson reported new 52-week Phase 3 ICONIC data showing ICOTYDE, its recently FDA‑approved oral IL‑23 receptor blocker for moderate‑to...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.